Plain-English translation of NCT06908252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a pilot study testing whether oral PrEP—a daily pill that prevents HIV infection—can be successfully offered to people who inject drugs through a mobile medical unit that also provides addiction treatment services. The researchers want to see if this approach works well and if people in the community see it as helpful and trustworthy.
People who inject drugs face significant risks for HIV infection, especially during times of crisis like the current overdose epidemic. This study exists to see if bringing HIV prevention directly to people through mobile services—alongside the addiction support they're already seeking—could be a practical and effective way to protect vulnerable communities.
If you join, you would receive oral PrEP pills to take daily as part of the services offered on the mobile medical unit. The study also includes conversations about your views on HIV prevention and your personal risk—helping researchers understand how people in the community feel about this type of service. The mobile unit brings care directly to you, making it easier to access both addiction support and HIV prevention in one place.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Duke University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment target
~7 participants
Started
September 2025
Primary completion
May 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.